Our investments place your capital at risk. We do not provide investment, tax or legal advice and we recommend you seek professional advice if you are considering investing with us. You may lose part or all of the amount you invest with us. We invest in unquoted shares in small companies. The value of these shares can be volatile, and the shares are often difficult to sell. The tax reliefs associated with our investments depend on the individual circumstances of each investor and may be subject to change. Past performance is not a reliable indicator of future results. Our forecasts and performance targets cannot accurately predict how investments will perform.
By
David Mott, Founder Partner, Oxford Capital
|
January 20, 2021
David Mott, Founder Partner, Oxford Capital As we start a new year, I’ve been reflecting on 2020 and all of the many challenges and opportunities that it brought. It struck me that just over a year ago we handled our first deep tech exit of the year, the sale of Latent Logic to Waymo (part…
By
Simon Edwards, Manager, Investor Relations
|
January 20, 2021
1. Prepare yourselves – make time and plan From experience, one of the biggest hurdles setting up Salesforce is managing the project around existing workloads, not just for the team or individuals who will be leading the project, but also any other team using it or inputting data. Make a plan that focuses on balancing…
Our portfolio company, Push Doctor has been chosen by Hounslow GP Practices (an area significantly impacted by Covid) to provide direct access to convenient digital NHS GP appointments for patients.
Good news for our portfolio company, Oxford BioTherapeutics – OBT and WuXi Biologics have selected a second bispecific programme that will combine an anti-PD-L1 antibody with OBT’s immuno-oncology candidate, OX003.
Curve has secured $95M in Series C funding to support its US launch and deepen its expansion into Europe. We first invested in Curve as an early stage company in 2017, back when it was a small, pre-revenue business with an energetic founder who really inspired us with his mission.
Positive news for our portfolio company, Oxford BioTherapeutics, it has announced a research collaboration with Kite, the global leader in cell therapy to evaluate five novel targets for a number of hematologic and solid tumor indications.
We feature in the latest EIS update from Intelligent Partnership, it includes an overview of the Oxford Capital Growth EIS and our views on the challenges and opportunities the industry faces in 2021.